Kyle Bass Lives Up To Big Pharma Patent ChallangeMark Melin
Legal papers from Kyle Bass-backed group challenge biotech company on their patents
Kyle Bass, founder of Dallas-based hedge fund Hayman Capital Management, appears to be making good on his announced plans to play Robin Hood with the top pharmaceutical companies.
Bass has now filed his first Inter Partes Review, a legal move challenging big pharma and their control over drug distribution and prices. His first target: Acorda Therapeutics, a biotechnology company based in Ardsley, New York. Their drugs primarily target neurological functions in people . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.